The prevalence of K-RAS mutation in pancreatic adenocarcinoma at the Johannesburg Academic Hospitals
No Thumbnail Available
Date
2020
Authors
Ngwenya, Sharol Philile
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
ABSTRACT
Introduction:
Pancreatic adenocarcinoma (PDAC) is a disease with a high mortality and morbidity worldwide
and current treatment options have proven largely ineffective. The tumour has certain well
recognised risk factors of which genetic risk factors are critical in the development thereof.
KRAS gene is the most commonly mutated gene and is an early event in the carcinogenesis.
Materials and Methods:
A retrospective study was performed of cases received at Johannesburg Academic Hospitals,
to determine the frequency of KRAS mutations in pancreatic adenocarcinoma. SNOMED search
from January 2006 and December 2010 revealed 132 cases of PDAC of which 40 randomly
selected cases underwent KRAS testing that proved successful in 28 cases. Five 3 μm thick
tissue sections of tumour were cut, and subjected to deoxyribonucleic acid (DNA) extraction.
The DNA product was amplified for KRAS exon 2 using polymerase chain reaction (PCR)
followed by DNA sequencing of the purified PCR amplicons.
Results:
Of the 28 patients, 11 were female (39.3%) and 17 males (60.7%). The age of the patients
ranged from 38 to 78 years with mean of 60.6 years (standard deviation of 9.6). KRAS
mutational analysis was performed on forty cases, successful in 28, 19 of which showed KRAS
mutations (67.9%).
Conclusion:
A high frequency of KRAS mutations in PDAC of 67.9% was noted in this study. The key to
managing this devastating neoplasm lies in targeted therapies against the KRAS pathway and
mutational testing for KRAS in pancreatic adenocarcinoma may become routine in the future
Description
A dissertation submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in fulfilment of the requirements for the degree of Master of Medicine (Anatomical Pathology), 2020